Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

Peripheral venous catheters cause over 10% of catheter-related bloodstream infections

A new study from Rhode Island Hospital has found that more than one in 10 catheter-related bloodstream infections due to Staph aureus in hospitalized adults are caused by infected peripheral venous catheters (PVC). The study points out the substantial medical burden that arises from complications from these infections due to the large number of such catheters used in hospitalized patients.

4 May 2011

Germ Genie is also effective against C.difficile infection

Scientists at the University of Hertfordshire, who proved the effectiveness of Germ Genie, a tool to prevent infections from keyboards, have now found that it can kill C.difficile.

3 May 2011

Leeds hospitals fined over levels of superbug related cases

According to latest figures the Methicillin-resistant Staphylococcus aureus (MRSA) superbug cases are again above allowed levels at Leeds hospitals and the hospitals are now facing a fine of £500,000 over failure to tackle the bug. As reported by the Yorkshire Evening Post earlier this year, every month that the number of MRSA cases exceeds a target agreed by health bosses, a fine of £100,000 is levied. Between April last year and the end of January, the target was breached four times.

3 May 2011

Affinium announces AFN-1252 Phase I study results in staphylococcal infections

Affinium Pharmaceuticals announced today the results of a new multiple ascending dose Phase I study of its novel, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation.

3 May 2011

New research shows honey fights drug-resistant germs

Herbal ingredients and natural nutrients are often capable of supporting different functions within the body, and current research is showing that a certain kind of honey may be useful in fighting drug-resistant germs.

2 May 2011

New innovative pilot project to combat surgical infections

Roughly one out of every 24 patients undergoing surgery acquires a surgical site infection. With 40 million operations performed in the U.S. each year, between 800,000 and 2 million individuals contract these infections annually.

29 Apr 2011

ViroPharma reports net sales of $127 million for first quarter 2011

ViroPharma Incorporated reported today its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

Low-cost colorimetric sensing array identifies bacterial infections

Bacterial infections really stink. And that could be the key to a fast diagnosis.

28 Apr 2011

Durata attains global rights for dalbavancin to treat abSSSI

Durata Therapeutics today announced the Company has attained worldwide rights for the development and commercialization of Durata's lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). In December 2010, Durata acquired from RaQualia Pharma commercialization rights for dalbavancin in Japan.

26 Apr 2011

FDA warns four firms to stop making unproven MRSA prevention claims

The U.S. Food and Drug Administration issued four warning letters to companies that manufacture and market over-the-counter (OTC) drug products, including hand sanitizers, that claim to prevent infection from methicillin-resistant Staphylococcus aureus bacteria (MRSA).

21 Apr 2011

Furiex acquires full rights to JNJ-Q2, a novel broad-spectrum fluoroquinolone antibiotic

Furiex Pharmaceuticals, Inc. announced today that it has acquired full exclusive license rights to develop and commercialize the compound JNJ-Q2 under its existing development and license agreement with Janssen Pharmaceutica N.V.. Furiex acquired these rights as a result of Janssen's decision not to exercise its option under the agreement that gave Janssen the opportunity to continue development of JNJ-Q2.

20 Apr 2011

Durata commences dalbavancin Phase 3 study in acute bacterial skin and skin structure infections

Durata Therapeutics today announced the Company initiated a global, pivotal, Phase 3 study (DISCOVER-1) of its lead product, dalbavancin, a long-acting, intravenous (IV) lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections (abSSSI). The pivotal study is being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA).

20 Apr 2011

Commonly used strategy has no effect in reducing MRSA, VRE in hospital ICUs

A new research study of the effect of a commonly used strategy to reduce the spread of antibiotic-resistant bacteria in hospital intensive care units shows that the strategy had no significant effect. That's the surprising finding of a multisite study led by Mayo Clinic investigators.

19 Apr 2011

Positive results from Nabriva's BC-3781 Phase II trial in ABSSSI

Nabriva Therapeutics today announced the successful results of a Phase II clinical trial of BC-3781 in acute bacterial skin and skin structure infections.

18 Apr 2011

Drug resistant bug plaguing the meat industry: Study

It has been found that nearly half of the meat and poultry (47 percent) sold in U.S. grocery stores is contaminated with Staphylococcus aureus (“Staph”), a bacteria linked to a wide range of human diseases, and this bacteria is resistant to at least three classes of antibiotics in more than half (52 percent) of contaminated samples. This comes from a nationwide study by the Translational Genomics Research Institute (TGen) published this week in the journal Clinical Infectious Diseases.

17 Apr 2011

New in vitro study results show that wound dressing with ionic silver kills strains of highly-resistant bacteria

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new in vitro study results showing that a wound dressing containing ionic silver is able to kill several strains of highly-resistant bacteria, commonly referred to as 'superbugs.'

16 Apr 2011

Study finds 47% of meat and poultry samples contaminated with S. aureus

Drug-resistant strains of Staphylococcus aureus, a bacteria linked to a wide range of human diseases, are present in meat and poultry from U.S. grocery stores at unexpectedly high rates, according to a nationwide study by the Translational Genomics Research Institute.

15 Apr 2011

Baxter's ARTISS phase III study results in face lift surgery presented at AAPS meeting

Baxter International Inc. announced today the results of a phase III study evaluating the safety and efficacy of ARTISS in 75 patients.

From Baxter International Inc. 12 Apr 2011

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, the independent Data Monitoring Committee recommended suspension of enrollment.

11 Apr 2011

SpectraShield surgical respirator receives FDA clearance to reduce MRSA infections

The U.S. Food and Drug Administration cleared the SpectraShield 9500 N95 surgical respirator, a device that kills 99.99 percent of three different kinds of bacteria when exposed to its outer surface.

11 Apr 2011